Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Receivables (2020 - 2023)

Revolution Medicines (RVMD) has 4 years of Receivables data on record, last reported at $1.3 million in Q4 2023.

  • For Q4 2023, Receivables fell 73.16% year-over-year to $1.3 million; the TTM value through Dec 2023 reached $1.3 million, down 73.16%, while the annual FY2023 figure was $1.3 million, 73.16% down from the prior year.
  • Receivables reached $1.3 million in Q4 2023 per RVMD's latest filing, up from $309000.0 in the prior quarter.
  • Across five years, Receivables topped out at $12.8 million in Q4 2020 and bottomed at $309000.0 in Q3 2023.
  • Average Receivables over 4 years is $5.3 million, with a median of $5.4 million recorded in 2022.
  • Peak YoY movement for Receivables: fell 13.83% in 2022, then crashed 93.74% in 2023.
  • A 4-year view of Receivables shows it stood at $12.8 million in 2020, then tumbled by 53.63% to $5.9 million in 2021, then dropped by 21.18% to $4.7 million in 2022, then crashed by 73.16% to $1.3 million in 2023.
  • Per Business Quant database, its latest 3 readings for Receivables were $1.3 million in Q4 2023, $309000.0 in Q3 2023, and $2.5 million in Q2 2023.